中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝病与肌少症双向关系的新见解与展望

冯巩 任艺琳 马永红 吴天悦 张佳怡 闫晓妮 宋娟娟 李雪萍 弥曼

引用本文:
Citation:

非酒精性脂肪性肝病与肌少症双向关系的新见解与展望

DOI: 10.3969/j.issn.1001-5256.2023.11.025
基金项目: 

‍陕西省教育厅重点项目-重点实验类 (21JZ050)

陕西省科技计划项目 (2022-JQ-986)

西安医学院2021年校级科研项目 (2021QN20)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:‍冯巩、任艺琳、吴天悦、张佳怡负责资料分析,撰写论文;冯巩、马永红、闫晓妮、宋娟娟参与文献检索,修改论文;冯巩、弥曼、李雪萍负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    李雪萍, lxp86@163.com (ORCID: 0000-0002-0556-9728)

    ‍弥曼, 853002274@qq.com (ORCID: 0000-0001-7408-5113)

Bidirectional relationship between nonalcoholic fatty liver disease and sarcopenia: New insights and perspectives

Research funding: 

‍Key Projects of Shaanxi Provincial Department of Education-Key Experimental Category (21JZ050);

Project of Provincial Department of Science and Technology (2022-JQ-986);

Research Projects of Xi’an Medical University at University Level in 2021 (2021QN20)

More Information
    Corresponding author: LI Xueping, lxp86@163.com (ORCID: 0000-0002-0556-9728); MI Man, 853002274@qq.com (ORCID: 0000-0001-7408-5113)
  • 摘要: 非酒精性脂肪性肝病(NAFLD)是一组高度异质性疾病,与代谢功能障碍密切相关。肌少症是指肌肉质量、强度和功能持续下降引起的综合征,与NAFLD常伴随出现。胰岛素抵抗是引起肌少症和NAFLD的主要病理机制,此外还有蛋白质和支链氨基酸的改变、高氨血症、肠道菌群、内分泌功能紊乱等因素也会共同导致肌少症和NAFLD。随着临床研究的不断深入,不少已发表的前瞻性研究文章已证实肌少症与NAFLD之间在病理生理上存在双向且复杂的关系。本文主要梳理了肌少症与NAFLD之间的双向关系,并在此基础上讨论了肌少症与NAFLD的共同发病机制,总结了本领域面临的挑战,为未来NAFLD与肌少症的双向关系研究提出了新的方向。

     

  • 图  1  肌少症和NAFLD共同发病的机制图

    Figure  1.  Mechanisms of copathogenesis of sarcopenia and NAFLD

  • [1] WANG CE, XU WT, GONG J, et al. Research progress in the treatment of non-alcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [2] SUN C, FAN JG. Characteristics and prevention strategies of patients with non-alcoholic fatty liver disease combined with sarcopenia[J]. Chin J Gastroenterol Hepatol, 2020, 29( 8): 841 ‍-‍845. DOI: 10.3969/j.issn.1006‍-‍5709.2020.08.001.

    孙超, 范建高. 非酒精性脂肪性肝病合并肌少症患者的特征和防治策略[J]. 胃肠病学和肝病学杂志, 2020, 29( 8): 841- 845. DOI: 10.3969/j.issn.1006-5709.2020.08.001.
    [3] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemidogy of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
    [4] LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4( 5): 389- 398. DOI: 10.1016/S2468-1253(19)30039-1.
    [5] JOO SK, KIM W. Interaction between sarcopenia and nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29( Suppl): S68- S78. DOI: 10.3350/cmh.2022.0358.
    [6] IANNUZZI-SUCICH M, PRESTWOOD KM, KENNY AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women[J]. J Gerontol A Biol Sci Med Sci, 2002, 57( 12): M772- M777. DOI: 10.1093/gerona/57.12.m772.
    [7] POUWELS S, SAKRAN N, GRAHAM Y, et al. Non-alcoholic fatty liver disease(NAFLD): a review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22( 1): 63. DOI: 10.1186/s12902-022-00980-1.
    [8] PÁR A, HEGYI JP, VÁNCSA S, et al. Sarcopenia-2021: Pathophysiology, diagnosis, therapy[J]. Orv Hetil, 2021, 162( 1): 3- 12. DOI: 10.1556/650.2021.32015.
    [9] CHOE EK, KANG HY, PARK B, et al. The association between nonalcoholic fatty liver disease and CT-measured skeletal muscle mass[J]. J Clin Med, 2018, 7( 10): 310. DOI: 10.3390/jcm7100310.
    [10] HONG HC, HWANG SY, CHOI HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study[J]. Hepatology, 2014, 59( 5): 1772- 1778. DOI: 10.1002/hep.26716.
    [11] LEE YH, JUNG KS, KIM SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys(KNHANES 2008-2011)[J]. J Hepatol, 2015, 63( 2): 486- 493. DOI: 10.1016/j.jhep.2015.02.051.
    [12] LEE YH, KIM SU, SONG K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys(KNHANES 2008-2011)[J]. Hepatology, 2016, 63( 3): 776- 786. DOI: 10.1002/hep.28376.
    [13] KIM HY, KIM CW, PARK CH, et al. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey[J]. Hepatobiliary Pancreat Dis Int, 2016, 15( 1): 39- 47. DOI: 10.1016/s1499-3872(15)60030-3.
    [14] KOO BK, KIM D, JOO SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis[J]. J Hepatol, 2017, 66( 1): 123- 131. DOI: 10.1016/j.jhep.2016.08.019.
    [15] PETTA S, CIMINNISI S, DI MARCO V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45( 4): 510- 518. DOI: 10.1111/apt.13889.
    [16] WIJARNPREECHA K, KIM D, RAYMOND P, et al. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA[J]. Eur J Gastroenterol Hepatol, 2019, 31( 9): 1121- 1128. DOI: 10.1097/MEG.0000000000001397.
    [17] KIM G, LEE SE, LEE YB, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study[J]. Hepatology, 2018, 68( 5): 1755- 1768. DOI: 10.1002/hep.30049.
    [18] HSIEH YC, JOO SK, KOO BK, et al. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression[J]. Clin Gastroenterol Hepatol, 2023, 21( 2): 388- 397. e 10. DOI: 10.1016/j.cgh.2022.01.020.
    [19] ISSA D, ALKHOURI N, TSIEN C, et al. Presence of sarcopenia(muscle wasting) in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2014, 60( 1): 428- 429. DOI: 10.1002/hep.26908.
    [20] SINN DH, KANG D, KANG M, et al. Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study[J]. Hepatology, 2022, 76( 6): 1746- 1754. DOI: 10.1002/hep.32578.
    [21] ROH E, HWANG SY, YOO HJ, et al. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study[J]. Hepatol Int, 2022, 16( 3): 545- 554. DOI: 10.1007/s12072-021-10258-8.
    [22] CANNATARO R, CARBONE L, PETRO JL, et al. Sarcopenia: etiology, nutritional approaches, and miRNAs[J]. Int J Mol Sci, 2021, 22( 18): 9724. DOI: 10.3390/ijms22189724.
    [23] NASSIR F. NAFLD: mechanisms, treatments, and biomarkers[J]. Biomolecules, 2022, 12( 6): 824. DOI: 10.3390/biom12060824.
    [24] BREEN L, PHILLIPS SM. Skeletal muscle protein metabolism in the elderly: Interventions to counteract the‘anabolic resistance’ of ageing[J]. Nutr Metab(Lond), 2011, 8: 68. DOI: 10.1186/1743-7075-8-68.
    [25] KAMIMURA H, SATO T, NATSUI K, et al. Molecular mechanisms and treatment of sarcopenia in liver disease: a review of current knowledge[J]. Int J Mol Sci, 2021, 22( 3): 1425. DOI: 10.3390/ijms22031425.
    [26] NEINAST M, MURASHIGE D, ARANY Z. Branched chain amino acids[J]. Annu Rev Physiol, 2019, 81: 139- 164. DOI: 10.1146/annurev-physiol-020518-114455.
    [27] MASTROTOTARO L, RODEN M. Insulin resistance and insulin sensitizing agents[J]. Metabolism, 2021, 125: 154892. DOI: 10.1016/j.metabol.2021.154892.
    [28] RINALDI L, PAFUNDI PC, GALIERO R, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. a narrative review[J]. Antioxidants(Basel), 2021, 10( 2): 270. DOI: 10.3390/antiox10020270.
    [29] LANG T, STREEPER T, CAWTHON P, et al. Sarcopenia: etiology, clinical consequences, intervention, and assessment[J]. Osteoporos Int, 2010, 21( 4): 543- 559. DOI: 10.1007/s00198-009-1059-y.
    [30] ZENG WL, WANG Y. Advances in ammonia lowering therapy for hepatic encephalopathy[J]. Liver, 2022, 27( 6): 622- 624. DOI: 10.14000/j.cnki.issn.1008-1704.2022.06.028.

    曾伟兰, 汪艳. 肝性脑病降氨治疗进展[J]. 肝脏, 2022, 27( 6): 622- 624. DOI: 10.14000/j.cnki.issn.1008-1704.2022.06.028.
    [31] QIU J, THAPALIYA S, RUNKANA A, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism[J]. Proc Natl Acad Sci U S A, 2013, 110( 45): 18162- 18167. DOI: 10.1073/pnas.1317049110.
    [32] OWEN OE, KALHAN SC, HANSON RW. The key role of anaplerosis and cataplerosis for citric acid cycle function[J]. J Biol Chem, 2002, 277( 34): 30409- 30412. DOI: 10.1074/jbc.R200006200.
    [33] ROMBOUTS K, MARRA F. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis[J]. Dig Dis, 2010, 28( 1): 229- 235. DOI: 10.1159/000282094.
    [34] WANG ZX, FAN JG. Relationships and mechanisms of sarcopenia and nonalcoholic fatty liver disease[J]. Int J Dig Dis, 2021, 41( 2): 88- 91, 107. DOI: 10.3969/j.issn.1673-534X.2021.02.004.

    王子璇, 范建高. 肌少症与非酒精性脂肪性肝病的关系及机制[J]. 国际消化病杂志, 2021, 41( 2): 88- 91, 107. DOI: 10.3969/j.issn.1673-534X.2021.02.004.
    [35] MIELE L, VALENZA V, LA TORRE G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J]. Hepatology, 2009, 49( 6): 1877- 1887. DOI: 10.1002/hep.22848.
    [36] TRIPATHI A, DEBELIUS J, BRENNER DA, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 7): 397- 411. DOI: 10.1038/s41575-018-0011-z.
    [37] SARKAR M, YATES K, SUZUKI A, et al. Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men[J]. Clin Gastroenterol Hepatol, 2021, 19( 2): 400- 402. e 2. DOI: 10.1016/j.cgh.2019.11.053.
    [38] KUMAR R, PRAKASH SS, PRIYADARSHI RN, et al. Sarcopenia in chronic liver disease: a metabolic perspective[J]. J Clin Transl Hepatol, 2022, 10( 6): 1213- 1222. DOI: 10.14218/JCTH.2022.00239.
    [39] DASARATHY S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease?[J]. Hepatology, 2014, 60( 1): 22- 25. DOI: 10.1002/hep.27134.
    [40] LI H, LIU DG, YAN SQ, et al. Improvement effect of 1,25(OH)2D3 combined with astragalus polysaccharide on insulin resistance of skeletal muscle cells in vitro and its mechanism[J]. J Jilin Univ(Med Edit), 2022, 48( 6): 1411- 1421. DOI: 10.13481/j.1671-587X.20220606.

    李浩, 刘东阁, 闫姝琪, 等. 1,25(OH)2D3联合黄芪多糖对体外骨骼肌细胞胰岛素抵抗的改善作用及其机制[J]. 吉林大学学报(医学版), 2022, 48( 6): 1411- 1421. DOI: 10.13481/j.1671-587X.20220606.
    [41] XIE Y, LIANG ZR, WANG J. Advances in research on the relationship between nonalcoholic fatty liver disease and vitamin D[J]. Transl Med J, 2021, 10( 5): 343- 346. DOI: 10.3969/j.issn.2095-3097.2021.05.015.

    谢艳, 梁子荣, 王钧. 非酒精性脂肪性肝病与维生素D关系研究进展[J]. 转化医学杂志, 2021, 10( 5): 343- 346. DOI: 10.3969/j.issn.2095-3097.2021.05.015.
    [42] HAMRICK MW. Role of the cytokine-like hormone leptin in muscle-bone crosstalk with aging[J]. J Bone Metab, 2017, 24( 1): 1- 8. DOI: 10.11005/jbm.2017.24.1.1.
    [43] YI Y, WANG C, DING Y, et al. Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the national health and nutrition examination survey III[J]. Front Endocrinol(Lausanne), 2023, 14: 1101892. DOI: 10.3389/fendo.2023.1101892.
    [44] PASCO JA, WILLIAMS LJ, JACKA FN, et al. Sarcopenia and the common mental disorders: a potential regulatory role of skeletal muscle on brain function?[J]. Curr Osteoporos Rep, 2015, 13( 5): 351- 357. DOI: 10.1007/s11914-015-0279-7.
    [45] SUBRAMANIAN M, WOJTUSCISZYN A, FAVRE L, et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management[J]. J Transl Med, 2020, 18( 1): 472. DOI: 10.1186/s12967-020-02658-5.
    [46] FENG G, WANG XY, LI SS, et al. Application of artificial intelligence and machine learning in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38( 10): 2352- 2356. DOI: 10.3969/j.issn.1001-5256.2022.10.029.

    冯巩, 王雪莹, 李珊珊, 等. 人工智能及机器学习在非酒精性脂肪性肝病中的应用[J]. 临床肝胆病杂志, 2022, 38( 10): 2352- 2356. DOI: 10.3969/j.issn.1001-5256.2022.10.029.
  • 加载中
图(1)
计量
  • 文章访问数:  128
  • HTML全文浏览量:  41
  • PDF下载量:  20
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-04-24
  • 录用日期:  2023-06-01
  • 出版日期:  2023-11-28
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回